Insider trade

Director sold ~$187M of CVS shares in the open market

Traded May 19, 2026 · Filed May 21, 2026

CVS HealthCVS

~$187M
Reported value · 1.98M sh @ $94.448: 6.21M
Holds after · shares reported: -9.5%
stock since the trade · S&P 500 +4.1%, $94.18 → $85.20 on Oct 1

Why it stands out

A board member of CVS Health sold $187M of CVS Health shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: May 19, 2026
Reporting period: Not applicable
Filed with the SEC: May 21, 2026

DirectorIndirect holding$1M+

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$187,326,935

Shares × reported transaction price

Timing vs results

13 days after results of May 6, 2026, 78 days before results of Aug 5, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $94.18 on May 19, 2026, within 5% of its 52-week high, after a 20% rise over the previous 30 trading days

52-week range $58.75 (Jul 24, 2025) to $98.11 (May 13, 2026), 90% of the way up, from 251 adjusted closes. 30 trading days earlier: $78.22 on Apr 7, 2026. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Mar 11, 2025 in the Court of Appeals for the First Circuit. A filing is an allegation, not a finding.

2 such cases were open. In Re: CVS Health Corp. Securities Act Litigation, docket 25-1230, via CourtListener (court records). Nature of suit 850, company named as first defendant

After it was reported

After	Stock	S&P 500	Difference
7 days	-2.4%	+1.4%	-3.9%
30 days	+8.6%	-0.2%	+8.8%
90 days	+0.4%	+2.3%	-1.9%

Past results only. Not a forecast.

Source receipt

Record ID: 0000905148-26-002617
Filed / recorded: May 21, 2026, 9:43 PM UTC
Added to OQRO: Oct 2, 2026, 3:52 AM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: CVS HEALTH Corp
Issuer CIK: 64803
Ticker: CVS
Reporting person: Larry Robbins
Relationship: Director
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: May 19, 2026
Transaction code: S
Shares / units: 1,983,387
Price per share: $94.448
Acquired / disposed: Disposed (D)
Shares owned after: 6,213,412
Ownership form: Indirect — Held by Glenview Investment Funds
Amendment: No

Footnotes from the filing

These shares of the Issuer's common stock (the "Shares") are held for the accounts of Glenview Capital Master Fund, Ltd., Glenview Offshore Opportunity Master Fund, Ltd. (the "GO Fund"), Glenview Healthcare Master Fund, L.P., and GCM Suggestivist I Master Fund, L.P. (collectively, the "Glenview Investment Funds").
This price reflects the weighted average price for open-market sales of Shares on May 19, 2026 within a $1.00 range. The actual prices for these transactions range from $94.18 to $95.175, inclusive. The Reporting Person further undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares sold at each separate price.
The Reporting Person disclaims beneficial ownership over any securities owned by the Glenview Investment Funds other than to the extent of any pecuniary interest he may have therein.
The Glenview Investment Funds are the record holders of the Shares. The Reporting Person is the Founder, Portfolio Manager and CIO of Glenview Capital Management, LLC, which serves as investment manager to each of the Glenview Investment Funds. The Reporting Person shares voting and dispositive power over the Shares held by the Glenview Investment Funds and may be deemed to beneficially own such Shares.